Vismodegib

Type: Keyphrase

Name: Vismodegib

First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

New Dermatology Findings from National Cancer Institute Reported

By a News Reporter-Staff News Editor at Drug Week Investigators publish new report on Dermatology. According to news reporting originating from Bethesda, Maryland, by NewsRx correspondents, research stated, "The discovery of mutations that activate hedgehog ... [Published Pharmacy Choice - Jun 12 2013]

Entities: Dermatology, National Cancer Institute, Vismodegib, Drugs, basal cell carcinoma

First reported Jun 04 2013 - Updated Jun 04 2013 - 1 reports

Valuing The Potential Of Cancer Drugs The Case Of Curis

The estimated market value of skin cancer and Basal Cell Carcinoma drugs, all drugs, is approx. $1.9 bn annually;The Curis drug, Erivedge® (vismodegib), now has been approved and is a drug for the treatment of Basal Cell Carcinoma, to the tune of $75,000 ... [Published BioPortfolio - Jun 04 2013]

Entities: Curis Incorporated, Drugs, Cancer, basal cell carcinoma

First reported Jun 03 2013 - Updated Jun 03 2013 - 1 reports

Valuing The Potential Of Cancer Drugs: The Case Of Curis

Curis (CRIS) is currently trading at $3.76 per share and is valued at $302.82 million.Conclusions on Curis' ValuationAs can be seen from the graph below, over the past 10 years Curis has not been the best investment, as the company's stock has bounced ... [Published Seeking Alpha - Jun 03 2013]

Entities: Curis Incorporated, Erivedge, Drugs, Cancer, Vismodegib

First reported May 28 2013 - Updated May 28 2013 - 1 reports

ERIVEDGE (Vismodegib) Capsule [Genentech, Inc.]

Updated Date: May 23, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - May 28 2013]

Entities: Vismodegib, Erivedge, Genentech Inc

First reported May 27 2013 - Updated May 27 2013 - 1 reports

Genentech Inc

ERIVEDGE (Vismodegib) Capsule [Genentech, Inc.]

Updated Date: May 23, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - May 27 2013]

Entities: Vismodegib, Erivedge, Genentech Inc

First reported May 23 2013 - Updated May 23 2013 - 1 reports

ERIVEDGE (Vismodegib) Capsule [Genentech, Inc.]

Updated Date: May 23, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - May 23 2013]

Entities: Vismodegib, Erivedge, Genentech Inc

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Present status and upcoming prospects of hedgehog pathway inhibitors in small cell lung cancer ...

Lung cancer is an important etiology of malignant mortality worldwide with global statistics indicating over 1 million deaths annually. Although there have been advances in cytotoxic chemotherapy, the prognosis after treatment still remains poor.Remarkably, ... [Published 7thSpace - May 22 2013]

Entities: small cell lung cancer, Porcupine, Lung Cancer, cytotoxic chemotherapy, Vismodegib

First reported May 20 2013 - Updated May 20 2013 - 1 reports

CURIS- Time to Assess Value Beyond Erivedge! - new market research report

Oral PI3K, BTK, Bcl-2 inhibitors are set to bring a change in treatment paradigm of hematological malignancies (CLL, iNHL, ALL). Curis's (CRIS) pipeline consists of a marketed drug Erivedge (L in US, R in EU/other, vismodegib, HedgeHog pathway inhibitor) ... [Published TransWorldNews - May 20 2013]

Entities: Erivedge, Curis Incorporated, Vismodegib, Mabthera

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Curis announces approval of Erivedge anti-cancer drug in Australia

Oncology-focused company Curis has announced the approval of Erivedge (vismodegib) in Australia for the treatment of metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma in adult patients who are not suitable for surgery and/or ... [Published PBR - News - May 13 2013]

Entities: Erivedge, Curis Incorporated, Australia, basal cell carcinoma

First reported Mar 05 2013 - Updated Mar 05 2013 - 1 reports

Drug Gets Better, but Pricey, Basal Cell Ca Results

MIAMI BEACH (MedPage Today) -- Surgical removal of basal cell carcinoma lesions resulted in smaller cosmetic defects in patients who received neoadjuvant vismodegib, according to results of a small clinical series, but the cost of the treatment was h ... [Published MedPageToday.com - medical news plus CME for ph ... - Mar 05 2013]

Entities: basal cell, Drugs, clinical series, Vismodegib, basal cell carcinoma

First reported Mar 01 2013 - Updated Mar 01 2013 - 1 reports

Blocking aPKC activity can stop growth of transplanted skin tumors resistant to vismodegib

Home » Syndicated Content » Hailed as a major step forward in the effort to develop targeted cancer therapies, a recently approved drug for the most common type of skin cancer has been a mixed blessing for patients. Although the initial response is usually ... [Published BioPortfolio - Mar 01 2013]

Entities: Vismodegib, Blocking, Tumor

Quotes

...According to news reporting originating from Bethesda, Maryland, by NewsRx correspondents, research stated, "The discovery of mutations that activate hedgehog (Hh) signaling in basal cell carcinoma (BCC) and other cancers has spurred the development of small molecule inhibitors that target the Hh pathway. High-throughput screens have identified a number of drug candidates that antagonize smoothened (SMO), an essential protein in the Hh signaling pathway."

New Dermatology Findings from National Cancer Institute Reported [Published Pharmacy Choice - Jun 12 2013]

...resistant to chemotherapy," explains Li, a professor of Biochemistry and Canada Research Chair in Cellular Proteomics and Functional Genomics. "So if we can prevent Numb from being methylated in cancer cells, then we will have the means to sensitize the cell to chemotherapy."

Research identifies a way to make cancer cells more responsive to chemotherapy [Published Brightsurf Science News - May 24 2013]

More From BioPortfolio on "Blocking aPKC activity can stop growth of transplanted skin tumors resistant to vismodegib"

Blocking aPKC activity can stop growth of transplanted skin tumors resistant to vismodegib [Published BioPortfolio - Mar 01 2013]

More Content

sort by: Date \| Relevance
New Dermatology Findings from National Cancer I... [Published Pharmacy Choice - Jun 12 2013]
Curis to Present at the 2013 Wells Fargo Securi... [Published Nasdaq - Jun 11 2013]
Valuing The Potential Of Cancer Drugs The Case ... [Published BioPortfolio - Jun 04 2013]
Healthcare Review: TESARO Inc, Nektar Therapeut... [Published BioMedReports - Jun 03 2013]
Valuing The Potential Of Cancer Drugs: The Case... [Published Seeking Alpha - Jun 03 2013]
Curis to Present at the Jefferies 2013 Global H... [Published Benzinga.com - May 30 2013]
ERIVEDGE (Vismodegib) Capsule [Genentech, Inc.] [Published DailyMed Drug Label Updates for the last seven ... - May 28 2013]
ERIVEDGE (Vismodegib) Capsule [Genentech, Inc.] [Published DailyMed Drug Label Updates for the last seven ... - May 27 2013]
Research identifies a way to make cancer cells ... [Published Brightsurf Science News - May 24 2013]
ERIVEDGE (Vismodegib) Capsule [Genentech, Inc.] [Published DailyMed Drug Label Updates for the last seven ... - May 23 2013]
Medical Breakthroughs 2013: Exposing Skin Cancer [Published Hudson Valley Magazine - May 22 2013]
Curis to Present at the Deutsche Bank 38th Annu... [Published Morningstar.com - May 22 2013]
Present status and upcoming prospects of hedgeh... [Published 7thSpace - May 22 2013]
CURIS- Time to Assess Value Beyond Erivedge! - ... [Published TransWorldNews - May 20 2013]
Curis announces approval of Erivedge anti-cance... [Published PBR - News - May 13 2013]
EU committee recommends conditional approval of... [Published PharmaBiz - Apr 30 2013]
Pending EC decision: Erivedge, vismodegib, Opin... [Published Pending EC decisions and European Public Assess ... - Apr 26 2013]
Curis to Release First Quarter 2013 Financial R... [Published GlobeNewswire: Acquisitions News - Apr 23 2013]
Drug Gets Better, but Pricey, Basal Cell Ca Res... [Published MedPageToday.com - medical news plus CME for ph ... - Mar 05 2013]
Blocking aPKC activity can stop growth of trans... [Published BioPortfolio - Mar 01 2013]
Infinata’s BioPharm Insight Releases its Cataly... [Published PRWeb - Feb 26 2013]
Curis to Release Fourth Quarter and Year End 20... [Published GlobeNewswire: Acquisitions News - Feb 13 2013]
Advances In Cancer 2012 [Published The Health Care Blog - Dec 28 2012]
Vismodegib team wins Drug Discovery of the Year... [Published BioPortfolio - Dec 19 2012]